Vertex Inc. (VERX)
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts.
Vertex, Inc. (VERX) Q1 2025 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Joe Crivelli - Vice President of Investor Relations David DeStefano - President and Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham & Company, LLC Christopher Quintero - Morgan Stanley Adam Hotchkiss - Goldman Sachs George Cruz - Citigroup Inc. Jake Roberge - William Blair & Company Kyle Aberasturi - BMO Capital Markets Alexander Sklar - Raymond James Financial, Inc. William Jellison - D.A. Davidson & Co. Rob Oliver - Robert W.
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex (VERX) Q1 Earnings and Revenues Top Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago.
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.
The company discloses narrower-than-expected access to its new painkiller.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell.
Why Vertex Pharmaceuticals Stock Is Sinking Today
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday.
Rising Costs Weigh on Vertex Q1 Earnings
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
